ACCRU Clinical Trials - Trial Spotlight

Clinical Trials

Trial Spotlight

Trial Spotlight

ACCRU conducts industry-sponsored and investigator-initiated cancer treatment and symptom management trials across many types of cancer. This feature highlights one of ACCRU’s recent or current innovative trials.

Breast Cancer Study for Premenopausal Women with ER+/HER2-Breast Cancer.

ACCRU Trial Spotlight

Premenopausal women diagnosed with ER+/HER2- breast cancer tend to have a more aggressive form of disease compared to women diagnosed in the postmenopausal setting and as such are aggressively treated with chemotherapy, ovarian function suppression and aromatase inhibitors. While this therapeutic strategy improves breast cancer specific outcomes, it is associated with substantial morbidity. ACCRU Study ATOS-Z-201, conducted by study chair Dr. Matthew Goetz and his team, focuses on developing an alternative endocrine approach for premenopausal breast cancer patients using endoxifen without ovarian function suppression and aims to mechanistically understand the basis for endoxifen’s superior anticancer effects. For more information on the study, go here:

Mantle Cell Lymphoma Study for R/R MCL Patients

ACCRU Trial Spotlight

In ACCRU Study LY-1806, principal investigator Dr. Catherine Diefenbach and her team seek to discover whether a new therapy is safe and effective for patients with relapsed mantle cell lymphoma. It has the potential to prolong the survival of R/R MCL patients, including BTK inhibitor-resistant patients, or even have a role in the frontline treatment of elderly or unfit patients who are ineligible for aggressive chemo-immunotherapy. For more information on the study, go here:

Mantle Cell Lymphoma Study for Transplant-Eligible Patients

ACCRU Trial Spotlight

In ACCRU Study LY1804, principal investigator Dr. Stephen Smith and his team seek to discover whether a high complete response rate can be achieved, including negativity for minimal residual disease. This is a Phase 2 optimization protocol that uses novel agents while reducing chemotheraphy dosing. For more information on the study go here: